At least one bi-dimensionally measurable lesion (greater than [>] . centimeters [cm] in its largest dimension by CT scan or magnetic resonance imaging [MRI])
At least one bi-dimensionally measurable lesion
Patients must have bi-dimensionally measurable disease (>=  cm) by CT imaging\r\n* NOTE: patients with marrow-only disease are eligible; response for these patients will be assessed by repeat bone marrow biopsy
Patients must have bi-dimensionally measurable disease (at least  cm); NOTE: patients with fully resected disease are eligible, and will be evaluable for all toxicity and efficacy endpoints except objective response
Patients must have bi-dimensionally measurable disease defined as at least one lesion that can be accurately measured in at least two planes in order to be eligible for this study
Patients must have bi-dimensionally measureable disease defined as at least one lesion that can be accurately measured in at least two planes
Subjects must have at least one bi-dimensionally measurable lesion; one of the measurements must be >= . cm in one dimension
Bi-lineage or bi-phenotypic leukemias
Patients must have measurable (>= . cm) or evaluable disease; baseline measurements and evaluations must be obtained within  days of registration to the study; abnormal PET scans will not constitute evaluable disease, unless verified by CT scan or other appropriate imaging; measurable disease must have at least one objective measurable disease parameter; a clearly defined, bi-dimensionally measurable defect or mass measuring at least . cm in diameter on a CT scan will constitute measurable disease; proof of lymphoma in the liver is required by a confirmation biopsy; skin lesions can be used as measurable disease provided bi-dimensional measurements are possible
Participant has ?  site of bi-dimensionally measurable disease measured using contrast enhanced MRI.
Presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (at least one objectively bi-dimensionally measurable (nodal) lesion (> cm in its largest dimension by CT scan).
At least one measurable GBM lesion that meets the following criteria:\r\n* Contrast enhancing and clearly defined, bi-dimensionally measurable margins, and\r\n* At least two perpendicular diameters measuring >=  mm and no diameters measuring >=  mm\r\n* (Note: MRI measurements will not include surgical cavity, cyst, or necrotic area)
Patients must have bi-dimensional measurable disease, as defined as radiographically apparent disease with the longest dimension of >= . cm
Non-WM must have at least one bi-dimensionally measurable lesion (that has not been previously irradiated) according to the Lugano Classification.
Patients affected by WM who do not have at least one bi-dimensionally measurable lesion in the baseline radiologic assessment must have measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a minimum IgM level ?  x upper limit of normal (ULN) and positive immunofixation test.
Patients affected by WM who do not have at least one bi-dimensionally measurable lesion in the baseline radiologic assessment must have measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a minimum IgM level ?  x upper limit of normal (ULN) and positive immunofixation test .
Patients must have measurable disease other than the injection site or biopsy site, i.e. greater than . cm bi-dimensionally on standard computed tomography imaging
Bi-dimensionally measurable disease (as per Revised Assessment in Neuro-Oncology [RANO] criteria)
Subjects must have bi-dimensionally measurable disease, defined as at least one lesion that can be accurately measured in at least two planes\r\n* This disease must be located primarily in the supratentorial region\r\n* Patients with significant disease that is metastatic outside of the supratentorial region are ineligible
Phase I (Cohorts T, and T): Greater than or equal to (>/=)  bi-dimensionally measurable lesion on computed tomography (CT) scan
At least one bi-dimensionally measurable nodal lesion >. cm in its longest diameter by computed tomography (CT) scan or MRI, as defined by the Lugano Classification
Must have at least one bi-dimensionally measurable lesion (greater than [>] . centimeters [cm] in its largest dimension by CT scan or Magnetic Resonance Imaging [MRI])
At least one bi-dimensionally measurable lesion (>. cm in its largest dimension by CT scan or magnetic resonance imaging [MRI])
At least one bi-dimensionally measurable lesion (greater than [>] . centimeters in its largest dimension by CT scan or magnetic resonance imaging)
Progression of bi-dimensionally measurable soft tissue (nodal metastasis) assessed within  month prior to registration by a CT scan or MRI of the abdomen and pelvis.
At least one bi-dimensionally measurable lesion on CT scan defined as more than (>) . centimeters (cm) in its longest dimension
At least one bi-dimensional measurable lesion
Bi-dimensionally measurable disease by palpation on clinical exam, or radiographic imaging per immune-related response criteria (irRC).
Bi-dimensionally measurable disease (> . cm).
Patients with measurable disease must have at least one objective measurable disease parameter; a clearly defined, bi-dimensionally measurable defect or mass measuring at least . cm in diameter on the CT portion of a PET/CT or CT scan or magnetic resonance imaging (MRI) (if appropriate) will constitute measurable disease; proof of lymphoma in the liver is required by a confirmation biopsy; skin lesions can be used as measurable disease provided bi-dimensional measurements are possible
Patients affected by WM, who do not have at least one bi-dimensionally measurable lesion in the baseline radiologic assessment, must have measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a minimum IgM level ?  x upper limit of normal (ULN)and positive immunofixation test.
The primary and nodal involvement must have been defined bi- or uni-dimensional measurements measurable by RECIST
Must have at least one bi-dimensionally measurable lesion ?. cm) documented by CT scan.
At least one bi-dimensionally measurable lesion (greater than [>]  cm in its largest dimension by computed tomography [CT] scan or magnetic resonance imaging [MRI])
All participants must have at least one bi-dimensionally measurable lesion (greater than [>]. centimeters (cm) in its largest dimension by computed tomography [CT] scan)
Measurable disease is defined as at least one bi-dimensionally measurable non-lymph node lesion greater than or equal to (>/=)  centimeter (cm) on long access diameter on computed tomography (CT) or magnetic resonance imaging (MRI) scan or at least one bi-dimensionally measurable lymph node measuring >/=. cm on short access diameter on CT or MRI scan
Presence of at least one lesion of bi-dimensionally measurable disease on baseline
Bi-dimensionally measurable disease within the bone
At least one bi-dimensionally measurable lesion on imaging scan defined as >. centimeters (cm) in its longest dimension
All patients must have bi-dimensionally measurable disease with lesions at least . cm in one dimension all measurable disease must be assessed within  days of registration
At least one bi-dimensionally measurable lesion on imaging scan defined as >. centimeters (cm) in its longest dimension
Prior treatment with BI .
At least two bi-dimensionally measurable nodal lesions ? . centimeters (cm) in its longest diameter by imaging
Patients must have bi-dimensional measurable disease
Must have bi-dimensionally measurable disease
